AHA · Chicago · 2026-11-06 – 2026-11-09
AHA Scientific Sessions 2026
1 de 21 ensaios Late-Breaking Science com resultadoOs resultados estão sob embargo até cada apresentação e surgem aqui assim que são divulgados.
sex., 6 de nov.
sáb., 7 de nov.
LBS.01 The Dr. Eugene Braunwald Late-Breaking Science Session: Translating Science into Prevention: Lessons from Landmark Trials
08:35–09:50 (America/Chicago) · Center Stage, North Hall, Level 3- 08:35ZEUSEstudo clínicoPrimary Report of the Ziltivekimab Cardiovascular Outcomes Trial (ZEUS)Apresentação sáb., 08:35
- 08:50Lp(a)HORIZON Estudo-chaveCardiologia · Lípidos · Lipoproteína(a)Em 8.323 doentes com doença cardiovascular estabelecida e Lp(a) ≥70 mg/dL, o pelacarsen 80 mg mensal não reduziu morte cardiovascular, enfarte do miocárdio, AVC ou revascularização urgente em comparação com placebo.Ler →
- 09:00Lp(a)HORIZON extended analysesEstudo observacionalExtended Analyses of Cardiovascular Outcomes With Pelacarsen Treatment in the Lp(a)Horizon TrialApresentação sáb., 09:00
LBS.02 Late-breaking Science: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After Stroke
13:45–14:45 (America/Chicago) · Center Stage, North Hall, Level 3- 13:45OCEANIC-STROKE FraminghamEstudo observacionalOutcomes in the OCEANIC-STROKE Randomized, Placebo-Controlled Trial: FXIa Inhibition by Asundexian in Participants With Non-Cardioembolic Stroke or Transient Ischemic Attack by Non-Laboratory Framingham Risk Score CategoryApresentação sáb., 13:45
- 14:00REDUCEEstudo clínicoA Randomized Controlled Trial of Spironolactone-Based Blood Pressure Management After StrokeApresentação sáb., 14:00
- 14:15OPTIMAL-StrokeEstudo clínicoIntensive Blood-Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Prior Stroke: The OPTIMAL-Stroke TrialApresentação sáb., 14:15
LBS.03 Late-breaking Science: Hot Topics in CVD Prevention
15:15–16:30 (America/Chicago) · Center Stage, North Hall, Level 3- 15:15STREAMEstudo clínicoDiscontinuing Statins in Multimorbid Older Adults Without Cardiovascular Disease: A Randomized Non-Inferiority Clinical TrialApresentação sáb., 15:15
- 15:30OPTIMAL-DIABETESEstudo clínicoIntensive Blood Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Type 2 Diabetes - The OPTIMAL-DIABETES TrialApresentação sáb., 15:30
- 15:45Ez-PAVEEstudo clínicoStatin-Ezetimibe Combination Therapy versus Statin Monotherapy in Patients With Atherosclerotic Cardiovascular Disease: Pre-Specified Second Randomization of the Ez-PAVE TrialApresentação sáb., 15:45
- 16:00Yoga-CaRe HFEstudo clínicoYoga-Based Cardiac Rehabilitation in Heart Failure With Reduced Ejection FractionApresentação sáb., 16:00
dom., 8 de nov.
LBS.04 Late-breaking Science: Innovations to Optimize Arrhythmia Care
15:30–16:45 (America/Chicago) · Center Stage, North Hall, Level 3- 15:30OptimPacingEstudo clínicoLeft Bundle Branch Pacing versus Right Ventricular Pacing for Atrioventricular Block: An International Multi-Center Randomized Controlled Trial (OptimPacing Study)Apresentação dom., 15:30
- 15:45COAST-AFEstudo clínicoCharacterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation: COAST-AF Randomized TrialApresentação dom., 15:45
- 16:00SUPERIOREstudo clínicoSacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled TrialApresentação dom., 16:00
- 16:15RACE-CARSEstudo clínicoRandomized Cluster Evaluation of Cardiac ARrest Systems (RACE-CARS) Trial Primary ResultsApresentação dom., 16:15
seg., 9 de nov.
LBS.05 Late-breaking Science: New Frontiers in Cardiometabolic Risk Reduction
08:00–09:15 (America/Chicago) · Center Stage, North Hall, Level 3- 08:00TYDAL-TIMI 78Estudo clínicoTYDAL-TIMI 78: A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol ConcentrationsApresentação seg., 08:00
- 08:15CTX310Estudo clínicoCRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b TrialApresentação seg., 08:15
- 08:30ATTAIN-OSAEstudo clínicoOrforglipron for the Treatment of Obstructive Sleep Apnea: Results From Attain-OSAApresentação seg., 08:30
- 08:45SYNCHRONIZE-CVOTEstudo clínicoSurvodutide and Cardiovascular Outcomes in Obesity: Results from the SYNCHRONIZE®-CVOT TrialApresentação seg., 08:45
LBS.06 Late-breaking Science: Artificial Intelligence in the Diagnosis of Cardiovascular Disease
09:45–11:00 (America/Chicago) · Center Stage, North Hall, Level 3- 09:55WATCH-LVEstudo observacionalConsumer Smartwatch Artificial Intelligence-Enabled Electrocardiogram for Left Ventricular Systolic Dysfunction: Cross-Manufacturer Validation and Serial Home MonitoringApresentação seg., 09:55
- 10:05PROVAR+Estudo observacionalAI-Enabled Tele-ECG Identifies Structural Heart Disease and Prioritizes Echocardiography in Underserved Populations: The PROVAR+ External Validation StudyApresentação seg., 10:05
- 10:22AI echo interpretation RCTEstudo clínicoAI-Assisted Comprehensive Echocardiographic Interpretation—A Blinded, Randomized Controlled TrialApresentação seg., 10:22